Results 11 to 20 of about 11,649,511 (362)

Natural products in drug discovery: advances and opportunities

Nature reviews. Drug discovery, 2021
Natural products and their structural analogues have historically made a major contribution to pharmacotherapy, especially for cancer and infectious diseases.
A. Atanasov, S. Zotchev, V. Dirsch, Ilkay Erdogan Maciej Judith M. Davide Wolfram Rudolf Edw Orhan Banach Rollinger Barreca Weckwerth Bauer Bay, I. Orhan, M. Banach, J. Rollinger, D. Barreca, W. Weckwerth, R. Bauer, E. Bayer, M. Majeed, A. Bishayee, V. Bochkov, G. Bonn, N. Braidy, F. Bucar, A. Cifuentes, G. D’Onofrio, Michael A. Bodkin, M. Diederich, A. Dinkova-Kostova, T. Efferth, Khalid El Bairi, N. Arkells, Tai-Ping Fan, B. Fiebich, M. Freissmuth, M. Georgiev, S. Gibbons, K. Godfrey, Christian W. Gruber, J. Heer, Lukas A. Huber, E. Ibáñez, A. Kijjoa, A. Kiss, Aiping Lu, F. A. Macias, Mark J. S. Miller, A. Mocan, Rolf Müller, Ferdinando Nicoletti, George Perry, V. Pittalà, L. Rastrelli, M. Ristow, G. Russo, A. S. Silva, D. Schuster, H. Sheridan, K. Skalicka‐Woźniak, L. Skaltsounis, E. Sobarzo-Sánchez, D. Bredt, H. Stuppner, A. Sureda, N. Tzvetkov, R. A. Vacca, Bharat B. Aggarwal, M. Battino, F. Giampieri, M. Wink, J. Wolfender, Jianbo Xiao, A. Yeung, G. Lizard, M. Popp, Michael Heinrich, I. Berindan‐Neagoe, M. Stadler, M. Daglia, R. Verpoorte, C. Supuran   +73 more
semanticscholar   +1 more source

Drugging Drug Resistance [PDF]

Cell, 2010
Resistance to anticancer drugs is widely observed in vitro and in cancer patients, but its prevalence is too high to be solely explained by the acquisition of mutations. Sharma et al. (2010) now report that dynamic chromatin modifications may be an independent route to drug resistance in cancer cells that can be reversed by epigenetic drugs.
Anton Berns, Jan-Hermen Dannenberg
openaire   +3 more sources

On Drugs

The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine, 2023
AbstractDespite their centrality to medicine, drugs are not easily defined. We introduce two desiderata for a basic definition of medical drugs. It should: (a) capture everything considered to be a drug in medical contexts and (b) rule out anything that is not considered to be a drug.
Baron, Samuel, Linton, Sara, O'Malley, Maureen A.   +2 more
openaire   +4 more sources

Engineering precision nanoparticles for drug delivery

Nature reviews. Drug discovery, 2020
In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental
M. J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, M. Wechsler, N. Peppas, R. Langer   +5 more
semanticscholar   +1 more source

A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing

Nature, 2020
A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals
D. Gordon, Gwendolyn M. Jang, Mehdi Bouhaddou, Jiewei Xu, K. Obernier, K. White, Matthew J. O’Meara, V. Rezelj, Jeffrey Z. Guo, D. Swaney, Tia A. Tummino, Ruth Hüttenhain, Robyn M. Kaake, Alicia L. Richards, B. Tutuncuoglu, Helene Foussard, J. Batra, Kelsey M. Haas, Mayank Modak, Minkyu Kim, Paige Haas, Benjamin J. Polacco, Hannes Braberg, Jacqueline M. Fabius, Manon Eckhardt, Margaret Soucheray, M. J. Bennett, Merve Cakir, Michael J. McGregor, Qiongyu Li, Bjoern Meyer, F. Roesch, T. Vallet, Alice Mac Kain, Lisa Miorin, Elena Moreno, Zun Zar Chi Naing, Yuan Zhou, S. Peng, Ying Shi, Ziyang Zhang, W. Shen, I. T. Kirby, James E. Melnyk, John S. Chorba, Kevin Lou, Shizhong A. Dai, Inigo Barrio-Hernandez, D. Memon, Claudia Hernandez-Armenta, Jiankun Lyu, Christopher J. P. Mathy, Tina Perica, K. B. Pilla, Sai J. Ganesan, Daniel J. Saltzberg, R. Rakesh, Xi Liu, S. Rosenthal, Lorenzo Calviello, S. Venkataramanan, José M Liboy-Lugo, Yizhu Lin, Xi-Ping Huang, Yongfeng Liu, S. Wankowicz, M. Bohn, M. Safari, Fatima S. Ugur, C. Koh, Nastaran Sadat Savar, Q. D. Tran, Djoshkun Shengjuler, S. Fletcher, M. C. O’Neal, Yiming Cai, Jason C. J. Chang, D. Broadhurst, Saker Klippsten, P. P. Sharp, Nicole A. Wenzell, Duygu Kuzuoglu-Ozturk, Hao-Yuan Wang, R. Trenker, Janet M. Young, D. A. Cavero, J. Hiatt, Theodore L. Roth, Ujjwal Rathore, Advait Subramanian, Julia Noack, Mathieu Hubert, R. Stroud, A. Frankel, O. Rosenberg, K. Verba, D. Agard, M. Ott, M. Emerman, N. Jura, M. von Zastrow, E. Verdin, A. Ashworth, O. Schwartz, C. d’Enfert, Shaeri Mukherjee, Matt Jacobson, Harmit S. Malik, D. Fujimori, T. Ideker, C. Craik, S. Floor, J. Fraser, J. Gross, A. Sali, B. Roth, D. Ruggero, J. Taunton, T. Kortemme, P. Beltrão, M. Vignuzzi, A. García-Sastre, K. Shokat, B. Shoichet, N. Krogan   +124 more
semanticscholar   +1 more source

Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-Naïve chronic HBV patients [PDF]

, 2013
Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.
Abedi, F., Alavian, S.M., Ataei, B., Azad, T.M., Daram, M., Fazeli, Z., Ghamari, S., Goodarzi, Z., Jazayeri, S.M., Judaki, M.A., Kalantari, E., Karimzadeh, H., Keyvani, H., Khedive, A., Mahabadi, M., Mahmoodi, M., Malekzadeh, R., Mansour-Ghanaei, F., Montazeri, G., Moradi, A., Nejatizadeh, A., Norouzi, M., Pourhosseingholi, M.A., Rafatpanah, H., Ramezani, F., Saberfar, E., Saberfiroozi, M., Samimirad, K., Sanei-Moghaddam, I., Sarizadeh, G., Sayad, B., Somi, M.H., Yaran, M., Ziee, M.   +33 more
core   +1 more source

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

Scientific Reports, 2017
To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.
Antoine Daina, O. Michielin, V. Zoete
semanticscholar   +1 more source

oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data

Briefings Bioinform., 2021
Cell line drug screening datasets can be utilized for a range of different drug discovery applications from drug biomarker discovery to building translational models of drug response.
D. Maeser, Robert F. Gruener, R. Huang
semanticscholar   +1 more source

Detecting a signal in the noise : Monitoring the global spread of novel psychoactive substances using media and other open source information [PDF]

, 2015
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no ...
Canadian Community Epidemiology Network On Drug Use, Center for Substance Abuse Research, European Monitoring Centre For Drugs And Drug Addiction, Sumnall H   +3 more
core   +1 more source

Deuterium in drug discovery: progress, opportunities and challenges

Nature reviews. Drug discovery, 2023
Substitution of a hydrogen atom with its heavy isotope deuterium entails the addition of one neutron to a molecule. Despite being a subtle change, this structural modification, known as deuteration, may improve the pharmacokinetic and/or toxicity profile
R. D. Di Martino, B. Maxwell, T. Pirali
semanticscholar   +1 more source